American Diversified Holdings Corporation (ADHC-OTC) Revises Projected Cost To Develop Auracis (TM) Migraine Device Therapy

Author's Avatar
Apr 12, 2019
Article's Main Image

DEL MAR, CA / ACCESSWIRE / October 23, 2018 / ADHC has revised its Projected Cost to Complete Auracis (Tens) Migraine Therapy. The cost of Engineering and Development to FDA Approval Over 2 year Time Frame has been reduced by $500,000 to $1.5 mm.